Retinal safety of intravitreal rtPA in healthy rats and under excitotoxic conditions.

Le 02 Nov 2021

Auteur : Daruich A, Parcq J, Delaunay K, Naud MC, Le Rouzic Q, Picard E, Crisanti P, Vivien D, Berdugo M, Behar-Cohen F

Année : 2016

Journal : Mol Vis 1090-0535

PubMed Id : 27881907

Intravitreal recombinant tissue plasminogen activator (rtPA) is used off-label for the surgical management of submacular hemorrhage, a severe complication of neovascular age-related macular degeneration. rtPA is approved for coronary and cerebral thrombolysis. However, in ischemic stroke rtPA is known to increase excitotoxic neural cell death by interacting with the N-methyl-D-aspartate (NMDA) receptor. We therefore investigated the retinal toxicity of rtPA in healthy rats and in a model of NMDA-induced retinal excitotoxicity.